Policy & Regulation
MHRA approves Efmody for adrenal insufficiency treatment
...
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
8 May 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that the European Commission has approved Sotyktu (deucravacitinib), alone or with methotrexate, for adults w...
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
...
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
8 May 2026 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Friday that the US Food and Drug Administration (FDA) has ...
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
8 May 2026 - South Korean biopharmaceutical company Mezzion Pharma Co Ltd on Thursday announced written feedback from the US Food and Drug Administration (FDA) following a pre-IND Type C Guidance meet...
Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87
8 May 2026 - Chance Pharmaceuticals, a clinical-stage biotech company focused on the research and development of innovative dry powder inhalation (DPI) therapies, announced on Thursday that the Center...